During a routine physical examination, flesh-colored papules were noted on a 36-year-old man’s elbows, knees, and interphalangeal joints. The patient reported that they had been present for a long time, were nonpruritic, and had remained the same color and size. He had not self-treated with any over-the-counter medications. His only other concern was acid reflux for which he regularly took antacids. He had no significant medical or surgical history and no medication allergy. He smoked 1 pack of cigarettes per day, drank alcohol socially, and consumed caffeine-containing drinks daily.
During a routine physical examination, flesh-colored papules were noted on a 36-year-old man’s elbows, knees, and interphalangeal joints. The patient reported that they had been present for a long time, were nonpruritic, and had remained the same color and size. He had not self-treated with any over-the-counter medications. His only other concern was acid reflux for which he regularly took antacids. He had no significant medical or surgical history and no medication allergy. He smoked 1 pack of cigarettes per day, drank alcohol socially, and consumed caffeine-containing drinks daily.
Vital signs were stable. The location of the lesions (shown here on the elbow, A) and their yellow-orange hue were characteristic of tuberous xanthomas. Total cholesterol level was 746 mg/dL; triglyceride level, 1730 mg/dL; and high-density cholesterol level, 38 mg/dL. Low-density cholesterol was not calculable. The remainder of the laboratory results were normal.
Lipid-lowering therapy with atorvastatin (40 mg/d) and fenofibrate (145 mg/d) was started. After 3 months of treatment, the patient’s total cholesterol level declined to 239 mg/dL and triglyceride level to 554 mg/dL; however, the skin lesions persisted. Slow-release nicotinic acid was then added; however, because of flushing, the patient was unable to tolerate this medication, and the dosage of atorvastatin was increased to 80 mg/d. After 6 months of treatment, the xanthomas had resolved (B).
Lebrikizumab Demonstrates Efficacy, Safety in Patients With Skin of Color With AD
June 11th 2025RAD 2025. Lebrikizumab improved skin clearance, itch, and pigmentation in patients with skin of color and atopic dermatitis, with strong safety data through 24 weeks, according to late-breaking data.